| 17.566 -0.354 (-1.98%) | 10-24 14:56 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 22.67 | 1-year : | 26.47 |
| Resists | First : | 19.4 | Second : | 22.67 |
| Pivot price | 15.17  |
|||
| Supports | First : | 14.02 | Second : | 10.69 |
| MAs | MA(5) : | 17.21 |
MA(20) : | 14.63 |
| MA(100) : | 9.01 |
MA(250) : | 8.24 |
|
| MACD | MACD : | 1.5 |
Signal : | 1.2 |
| %K %D | K(14,3) : | 66.7 |
D(3) : | 67.6  |
| RSI | RSI(14): 69.5 |
|||
| 52-week | High : | 19.4 | Low : | 3.39 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ AVTX ] has closed below upper band by 7.5%. Bollinger Bands are 144% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 4 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 19.22 - 19.3 | 19.3 - 19.36 |
| Low: | 16.35 - 16.43 | 16.43 - 16.5 |
| Close: | 17.77 - 17.91 | 17.91 - 18.04 |
Avalo Therapeutics, Inc., a clinical-stage precision medicine company, discovers, develops, and commercializes targeted therapeutics for patients with unmet clinical need in immunology, immuno-oncology, and rare genetic diseases. It develops AVTX-002, a fully human anti-LIGHT monoclonal antibody, which is under Phase II clinical trial for the treatment of non-eosinophilic asthma, as well as inflammatory bowel disease, including moderate to severe Crohn's disease, and ulcerative colitis; and Phase III clinical trial for the treatment of COVID-19 acute respiratory distress syndrome. The company also engages in developing AVTX-007, a fully human Anti-IL-18 monoclonal antibody that is under Phase I clinical trial for the treatment of still's disease, including adult-onset still's disease and systemic juvenile idiopathic arthritis. Its products for rare genetic diseases in Phase III clinical trials include AVTX-801, a D-galactose substrate replacement therapy for the treatment of phosphoglucomutase 1 deficiency (PGM1), also known as PGM1-CDG; and AVTX-803, a L-fucose substrate replacement therapy for the treatment of LADII, also known as SLC35C1-CDG. The company was formerly known as Cerecor Inc. and changed its name to Avalo Therapeutics, Inc. in August 2021. Avalo Therapeutics, Inc. was incorporated in 2011 and is headquartered in Rockville, Maryland.
Sat, 18 Oct 2025
Piper Sandler Sticks to Its Buy Rating for Avalo Therapeutics (AVTX) - The Globe and Mail
Fri, 10 Oct 2025
Avalo Therapeutics, Inc. Updates Investor Presentation - TradingView
Wed, 01 Oct 2025
Avalo Therapeutics Expands Leadership Team with Key - GlobeNewswire
Tue, 30 Sep 2025
BTIG Reiterates Avalo Therapeutics (AVTX) Buy Recommendation - Nasdaq
Mon, 22 Sep 2025
Avalo Therapeutics Appoints Kevin R. Lind to Board of Directors - GlobeNewswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 18 (M) |
| Held by Insiders | 6.95e+006 (%) |
| Held by Institutions | 5.2 (%) |
| Shares Short | 56 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -5.978e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -13 % |
| Return on Assets (ttm) | 640.5 % |
| Return on Equity (ttm) | -32.1 % |
| Qtrly Rev. Growth | 441000 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | -95 |
| EBITDA (p.s.) | -2.96421e+007 |
| Qtrly Earnings Growth | 6.5 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -47 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.19 |
| Price to Cash Flow | 1.75 |
| Dividend | 0 |
| Forward Dividend | 1.24e+006 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|